Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Cryoablation in Advanced NSCLC
NCT07053215Completed
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by The First Hospital of Hebei Medical University. Started Dec 2020; status: completed.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07053215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053215.